Payment overview · 2025
General Payments
$393.83
18 reported records · 6 companies
Healthcare provider profile · identity verified
Darryl Aliggayu, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALBANY, NY · NPI 1982923116
Verified facts
What the public records show
CMS Open Payments records show Darryl Aliggayu, MD received $393.83 in general payments during 2025 across 18 reported records.
GlaxoSmithKline, LLC. accounted for 48.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 180 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $189.65 | 48.2% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.91 | 14.2% | 2 | 2025 |
| Renalytix AI, Inc. | Unresolved — no canonical attribution shown | $51.15 | 13.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $45.66 | 11.6% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $27.84 | 7.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $23.62 | 6.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $393.83 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $167.99 | 8 | 2025 |
Source payment records
|
|||||
| KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT Normalized: kidneyintelx blood collection convenience kit |
Device | Renalytix AI, Inc. | $51.15 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $45.66 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $34.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $34.76 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $27.84 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $23.62 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $21.66 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 180 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 70 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
180 | 26 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 591 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 401 | 119 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 288 | 33 |
| Gabapentin | Gabapentin | 272 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 269 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 219 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 201 | 54 |
| Ozempic | Semaglutide | 180 | 26 |
| Omeprazole | Omeprazole | 177 | 59 |
| Losartan Potassium | Losartan Potassium | 176 | 56 |
| Lisinopril | Lisinopril | 170 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 52 |
| Oxycodone Hcl | Oxycodone Hcl | 166 | 18 |
| Metformin Hcl | Metformin Hcl | 158 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 151 | 51 |
| Famotidine | Famotidine | 125 | 34 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 119 | 22 |
| Eliquis | Apixaban | 117 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 32 |
| Fluticasone Propionate | Fluticasone Propionate | 106 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 96 | 27 |
| Jardiance | Empagliflozin | 95 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 92 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 15 |
| Alprazolam | Alprazolam | 90 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 90 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 14 |
| Sertraline Hcl | Sertraline Hcl | 89 | 28 |
| Montelukast Sodium | Montelukast Sodium | 72 | 13 |
| Trazodone Hcl | Trazodone Hcl | 71 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 70 | 16 |
| Prednisone | Prednisone | 66 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 63 | 15 |
| Furosemide | Furosemide | 63 | 22 |
| Carvedilol | Carvedilol | 62 | 26 |
| Mirtazapine | Mirtazapine | 57 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 49 | 14 |
| Allopurinol | Allopurinol | 47 | 11 |
| Ezetimibe | Ezetimibe | 47 | 12 |
| Spironolactone | Spironolactone | 47 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 43 | 13 |
| Simvastatin | Simvastatin | 43 | 14 |
| Amoxicillin | Amoxicillin | 40 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 20 |
| Pregabalin | Pregabalin | 40 | suppressed |
| Tradjenta | Linagliptin | 40 | 11 |
| Azithromycin | Azithromycin | 39 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 39 | 14 |
| Telmisartan | Telmisartan | 37 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 29 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | suppressed |
| Linzess | Linaclotide | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Aripiprazole | Aripiprazole | 27 | suppressed |
| Belsomra | Suvorexant | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 26 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 14 |
| Risperidone | Risperidone | 25 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Buprenorphine | Buprenorphine | 21 | suppressed |
| Potassium Chloride | Potassium Chloride | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Repaglinide | Repaglinide | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 12 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $393.83 · 18 records | GlaxoSmithKline, LLC. | AREXVY, KIDNEYINTELX BLOOD COLLECTION CONVENIENCE KIT, Ohtuvayre, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Wegovy, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error